TABLE 2

Performances of three commercially available chemiluminescent immunoassays in detecting VCA IgG, VCA IgM, and EBNA-1 IgG antibodies compared with those of immunofluorescence assays as reference

ImmunoassaySensitivity (%)Specificity (%)
VCA IgMVCA IgGEBNA-1-IgGVCA IgMVCA IgGEBNA-1-IgG
Architecta91.099.296.799.486.299.1
DiaSorin
    Meridianb92.286.990.698.094.432.2
    In-housec94.490.295.976.995.883.3
Siemensd77.994.493.895.810076.6
  • a Sera tested by the Architect EBV panel were categorized as true or false positives/negatives on the basis of their agreement or disagreement with immunofluorescence assay results. Sera displaying values within the gray zone of the respective assay were excluded from the analyses.

  • b The performances of the Liaison VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent assays (CLIAs) (DiaSorin, Saluggia, Italy) were evaluated using theIF assays from Meridian (like in the current study) as a reference (4).

  • c The performances of the Liaison VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent assays were evaluated using in-houseIF assays as a reference (5).

  • d The Immulite 2000 CLIA (Siemens, Germany) was evaluated using theIF assays from Meridian (like in the current study) as a reference (4).